New Nitro PDF Pro Release Enables Accessible, Inclusive and Compliant PDFs for All
18.5.2023 16:57:00 EEST | Business Wire | Press release
Nitro Software, a global leader in SaaS PDF, eSign and business document solutions, launched new document accessibility features as part of the latest release of Nitro PDF Pro, its flagship product. Driven by its mission to provide easy-to-use, inclusive and compliant technology for all people and organizations, Nitro teamed up with digital accessibility solution provider Level Access.
“Everyone deserves access to digital information, and that includes the more than 1.3 billion people globally who identify as having a disability,” says Jonathon Avila, Chief Accessibility Officer at Level Access. “It has been deeply rewarding to support Nitro in providing innovative solutions that contribute to a more accessible digital world.”
Why do organizations need tools to create accessible PDF documents?
Document accessibility features are used by people with a range of needs, including those who are blind or have low vision. For organizations, particularly in higher education and government, accessibility features have a far-reaching and long-term impact on goals including:
Inclusivity: All people, including people with disabilities, should be equipped with technology that enables their success. With document accessibility tools, people with disabilities can participate and contribute equitably in education, the professional world and their communities.
Recruiting: Meeting the needs of all employees is a key differentiator for organizations during the recruiting and hiring process. Companies that prioritize the accessibility of documents and other digital information are at an advantage when competing for diverse talent.
Compliance: Many organizations are legally required to procure technology that meets accessibility compliance standards.
How is Nitro making documents more accessible and inclusive?
The latest Nitro PDF Pro release provides an intuitive solution for a vast and growing market seeking reliable tools that ensure document accessibility, inclusivity and compliance.
“Whether permanent, temporary or situational, we are all likely to experience disabilities in our lives. Nitro is a diverse and inclusive company, and we are proud that our latest release of Nitro PDF Pro provides capabilities for equal access to PDFs in the workplace, classroom, at home and everywhere in between,” says Sam Thorpe, Nitro’s Chief Product Officer. “The partnership with Level Access has been exceptionally valuable to ensure the software we design is aligned to the accessibility needs of people and organizations around the world.”
New features and enhancements in the latest release of Nitro PDF Pro include:
-
Accessibility features making it fast and easy to create accessible, compliant PDFs, such as:
- Auto-tagging documents, tables and lists in a few simple steps
- Assigning accessibility tags, roles and reading order in tagged PDFs
- Managing artifacts
- Specifying human languages of tagged PDFs
- Embedding fonts
- Supplying alternate text
- Marking PDF/UA compliance
- Fresh new UI with a modern, easy-to-navigate experience
- Expanded list of language installers
To learn more about creating accessible and compliant PDFs, join Nitro and Level Access for an educational webinar on June 8, 2023.
Explore more of what’s new in the latest release of Nitro PDF Pro.
About Nitro Software
Nitro is a global SaaS leader in PDF document management and eSigning. Nitro’s Productivity Platform includes powerful PDF tools, digital workflow automation, highly secure eSigning and identity capabilities. Its analytics solution measures and quantifies ROI, usage and sustainability impact. With a best-in-class customer success team, Nitro supports more than 67% of the Fortune 500, 3 million licensed users and 13,000+ business customers across 157 countries. For more information: visit https://gonitro.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230518005546/en/
Contact information
Media Contacts
Nitro Software media@gonitro.com
Bospar for Nitro Software prfornitro@bospar.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 17:44:00 EET | Press release
Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the production line. In-Factory Profile Provisioning (IFPP) addresses this challenge by enabling conne
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom